Clean Room Lessons from FDA’s Compounding Pharmacy Inspections
This article was originally published in The Gold Sheet
Reacting to last fall’s fungal meningitis crisis, FDA has inspected more than 50 compounding pharmacies this year looking for poor aseptic practices. What it found makes for a sobering training tool on sterility assurance.
You may also be interested in...
As FDA, Congress and the courts stumbled, compounding pharmacies such as NECC took advantage of a gray area of the law. Legislators will get another try; one proposed subjecting such pharmacies to cGMP requirements.
The US FDA has issued guidance on how it will continue to use remote technology to assess agency regulated facilities, a practice that became popular during COVID-19 travel restrictions.
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.